Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bipartisan AER Bill Requires Reporting For All OTC Drugs, Supplements

This article was originally published in The Tan Sheet

Executive Summary

Manufacturers of nonprescription drugs and dietary supplements will have to provide company contact information on product labels in order for consumers to report serious adverse events associated with the products under long-awaited legislation introduced June 21

Related Content

Supplement Adverse Event Reports Grow, But FDA Says 'Serious' Intel Is Short
AER Bills Likely To See Action In November Lame Duck Session
Ephedra: Experts Speak Out On The Good, The Bad And The Ugly
CRN Legislative Briefing Addresses Pending Supplement Bills, Needed Policy
AER Bill Will Provide Documented History Of Supplement Safety – Industry
“MedWatch Plus” Will Create Single Adverse Event Reporting Venue
Durbin Renews Supplement AER Efforts With Defense Bill Amendment
Dietary Supplement AER Bill Fails To Pass California Legislature
Dietary Supplement AER Bill Fails To Pass California Legislature
Senators Durbin, Hatch To Work Together On AER Plan





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts